Evidence for a Major Role of Heredity in Graves' Disease: A Population-Based Study of Two Danish Twin Cohorts

2001 ◽  
Vol 86 (2) ◽  
pp. 930-934 ◽  
Author(s):  
T. H. Brix
Keyword(s):  
Population Based ◽  
Graves Disease ◽  
Population Based Study ◽  
Danish Twin

scholarly journals Evidence for a Major Role of Heredity in Graves’ Disease: A Population-Based Study of Two Danish Twin Cohorts1

2001 ◽  
Vol 86 (2) ◽  
pp. 930-934 ◽  
Author(s):  
Thomas Heiberg Brix ◽  
Kirsten Ohm Kyvik ◽  
Kaare Christensen ◽  
Laszlo Hegedüs
Keyword(s):  
Population Based ◽  
Graves Disease ◽  
Population Based Study ◽  
Danish Twin

Willingness to cooperate with police: A population-based study of Australian young adult illicit stimulant users

2016 ◽  
Vol 17 (3) ◽  
pp. 301-318 ◽  
Author(s):  
Ellen M Leslie ◽  
Adrian Cherney ◽  
Andrew Smirnov ◽  
Helene Wells ◽  
Robert Kemp ◽  
...  
Keyword(s):  
Young Adult ◽  
Procedural Justice ◽  
Drug Users ◽  
Illicit Drug ◽  
Population Based ◽  
Police Legitimacy ◽  
Population Based Study ◽  
Reduction Strategies ◽  
Willingness To Cooperate

While procedural justice has been highlighted as a key strategy for promoting cooperation with police, little is known about this model’s applicability to subgroups engaged in illegal behaviour, such as illicit drug users. This study compares willingness to cooperate with police and belief in police legitimacy, procedural justice and law legitimacy among a population-based sample of Australian young adult amphetamine-type stimulant (ATS; i.e. ecstasy and methamphetamine) users and non-users. We then examine predictors of willingness to cooperate among ATS users. ATS users were significantly less willing to cooperate with police and had significantly lower perceptions of police legitimacy, procedural justice and law legitimacy, compared to non-users. However, belief in police legitimacy independently predicted willingness to cooperate among ATS users. We set out to discuss the implications of these findings for policing, including the role of procedural justice in helping police deliver harm reduction strategies.

P-646 Pregnancy outcomes in women with panhypopituitarism - A population-based study

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
I Feferkorn ◽  
A Badeghiesh ◽  
H Baghlaf ◽  
M Dahan
Keyword(s):  
Gestational Diabetes ◽  
Maternal Death ◽  
Pregnancy Outcomes ◽  
Post Partum ◽  
Population Based ◽  
Neonatal Outcomes ◽  
Pituitary Hormone ◽  
Population Based Study ◽  
Post Partum Hemorrhage

Abstract Study question What are the consequences of panhypopituitarism on pregnancy outcomes? Summary answer After controlling for confounding effects, women with panhypopituitarism have a higher prevalence of adverse obstetrical (including post-partum hemorrhage, hysterectomy and maternal death) and neonatal outcomes. What is known already Panhypopituitarism is a condition of inadequate or absent anterior pituitary hormone production. Pregnancy in women with panhypopituitarism is uncommon and there is only limited data (mainly case reports) regarding pregnancy outcomes in these women. Given the scarcity of data we sought to assess the association between panhypopituitarism and obstetrical and neonatal outcomes. Study design, size, duration A retrospective population-based study utilizing data from the Healthcare Cost and Utilization Project—Nationwide Inpatient Sample (HCUP-NIS). A dataset of all deliveries between 2004 and 2014 inclusively, was created. Within this group, all deliveries to women who had a diagnosis of panhypopituitarism during pregnancy were identified as part of the study group (n = 179), and the remaining deliveries comprised the reference group (n = 9,096,609). Participants/materials, setting, methods The HCUP-NIS is the largest inpatient sample database in the USA, and it is comprised of hospitalizations throughout the country. It provides information relating to 20% of US admissions and represents over 96% of the American population. Multivariate logistic regression analysis, controlling for confounding effects, was conducted to explore associations between panhypopituitarism and delivery and neonatal outcomes. According to Tri-Council Policy statement (2018), IRB approval was not required, given data was anonymous and publicly available. Main results and the role of chance Women with a diagnosis of panhypopituitarism were more likely to be older, to have a diagnosis of chronic hypertension, to have a diagnosis of pre-gestational diabetes mellitus and to be carrying twins or a higher order pregnancy (all p < 0.0001), than the controls. A significantly higher risk of post-partum hemorrhage (adjusted odds ratio-aOR:3.52; 95%CI:2.18–5.69,p < 0.0001), maternal infection (aOR:3.97; 95%CI:2.30–6.85,p < 0.0001), pulmonary embolism (aOR:14.90; 95%CI:2.06–107.82,p < 0.007), disseminated intravascular coagulation (aOR:20.29; 95%CI:10.60–38.85,p < 0.0001), maternal death (aOR:31.90; 95%CI:3.33–234.85,p = 0.001) and congenital anomalies (aOR:4.55; 95CI:1.86–11.16,p = 0.001), were found among the panhypopituitarism patients. Surprisingly, there was a lower incidence of caesarean delivery (aOR:0.69; 95%CI:0.50–0.96,p = 0.026) in the panhypopituitarism patients than the controls. No significant difference was found in the rate of pregnancy induced hypertension (95%CI:0.78-1.97), gestational hypertension (95%CI:0.14-1.41), preeclampsia (95%CI:0.96-2.99), gestational diabetes (95%CI:0.30-1.01), preterm delivery (95%CI:0.74-1.91), preterm premature rupture of membranes (95%CI:0.17-2.82), operative vaginal delivery (95%CI: 0.23-1.19), small for gestational age neonates (95%CI:0.27-2.02) or intra-uterine fetal demise (95%CI:0.13-6.71). Limitations, reasons for caution The limitations of our study are its retrospective nature and the fact that it relies on an administrative database. The severity of specific hormonal deficiencies and the presence and magnitude of posterior pituitary hormone deficiencies could not be assessed, nor could compliance with hormone replacement. Wider implications of the findings Until now, no control studies of outcomes with panhypopituitaryism in pregnancy are available in the medical literature. Physicians should be aware of and try to prevent the above possible maternal and fetal complications related to this endocrinopathy. Future studies should evaluate the role of medication compliance with pregnancy outcomes. Trial registration number not applicable

P–646 Pregnancy outcomes in women with panhypopituitarism - A population-based study

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
I Feferkorn ◽  
A Badeghiesh ◽  
H Baghlaf ◽  
M Dahan
Keyword(s):  
Gestational Diabetes ◽  
Maternal Death ◽  
Pregnancy Outcomes ◽  
Post Partum ◽  
Population Based ◽  
Neonatal Outcomes ◽  
Pituitary Hormone ◽  
Population Based Study ◽  
Post Partum Hemorrhage

Abstract Study question What are the consequences of panhypopituitarism on pregnancy outcomes? Summary answer After controlling for confounding effects, women with panhypopituitarism have a higher prevalence of adverse obstetrical (including post-partum hemorrhage, hysterectomy and maternal death) and neonatal outcomes. What is known already Panhypopituitarism is a condition of inadequate or absent anterior pituitary hormone production. Pregnancy in women with panhypopituitarism is uncommon and there is only limited data (mainly case reports) regarding pregnancy outcomes in these women. Given the scarcity of data we sought to assess the association between panhypopituitarism and obstetrical and neonatal outcomes. Study design, size, duration A retrospective population-based study utilizing data from the Healthcare Cost and Utilization Project—Nationwide Inpatient Sample (HCUP-NIS). A dataset of all deliveries between 2004 and 2014 inclusively, was created. Within this group, all deliveries to women who had a diagnosis of panhypopituitarism during pregnancy were identified as part of the study group (n = 179), and the remaining deliveries comprised the reference group (n = 9,096,609). Participants/materials, setting, methods The HCUP-NIS is the largest inpatient sample database in the USA, and it is comprised of hospitalizations throughout the country. It provides information relating to 20% of US admissions and represents over 96% of the American population. Multivariate logistic regression analysis, controlling for confounding effects, was conducted to explore associations between panhypopituitarism and delivery and neonatal outcomes. According to Tri-Council Policy statement (2018), IRB approval was not required, given data was anonymous and publicly available. Main results and the role of chance Women with a diagnosis of panhypopituitarism were more likely to be older, to have a diagnosis of chronic hypertension, to have a diagnosis of pre-gestational diabetes mellitus and to be carrying twins or a higher order pregnancy (all p < 0.0001), than the controls. A significantly higher risk of post-partum hemorrhage (adjusted odds ratio-aOR:3.52; 95%CI:2.18–5.69,p<0.0001), maternal infection (aOR:3.97; 95%CI:2.30–6.85,p<0.0001), pulmonary embolism (aOR:14.90; 95%CI:2.06–107.82,p<0.007), disseminated intravascular coagulation (aOR:20.29; 95%CI:10.60–38.85,p< 0.0001), maternal death (aOR:31.90; 95%CI:3.33–234.85,p=0.001) and congenital anomalies (aOR:4.55; 95CI:1.86–11.16,p=0.001), were found among the panhypopituitarism patients. Surprisingly, there was a lower incidence of caesarean delivery (aOR:0.69; 95%CI:0.50–0.96,p=0.026) in the panhypopituitarism patients than the controls. No significant difference was found in the rate of pregnancy induced hypertension (95%CI:0.78–1.97), gestational hypertension (95%CI:0.14–1.41), preeclampsia (95%CI:0.96–2.99), gestational diabetes (95%CI:0.30–1.01), preterm delivery (95%CI:0.74–1.91), preterm premature rupture of membranes (95%CI:0.17–2.82), operative vaginal delivery (95%CI:0.23–1.19), small for gestational age neonates (95%CI:0.27–2.02) or intra-uterine fetal demise (95%CI:0.13–6.71). Limitations, reasons for caution The limitations of our study are its retrospective nature and the fact that it relies on an administrative database. The severity of specific hormonal deficiencies and the presence and magnitude of posterior pituitary hormone deficiencies could not be assessed, nor could compliance with hormone replacement. Wider implications of the findings: Until now, no control studies of outcomes with panhypopituitaryism in pregnancy are available in the medical literature. Physicians should be aware of and try to prevent the above possible maternal and fetal complications related to this endocrinopathy. Future studies should evaluate the role of medication compliance with pregnancy outcomes. Trial registration number Not applicable

The role of sex in the outcomes of patients with biliary tract cancers remains unclear: A population-based study

2018 ◽  
Vol 216 (6) ◽  
pp. 1118-1121
Author(s):  
Madeline Lemke ◽  
Yvonne DeWit ◽  
Sulaiman Nanji ◽  
Christopher M. Booth ◽  
Jennifer A. Flemming
Keyword(s):  
Biliary Tract ◽  
Population Based ◽  
Population Based Study ◽  
Biliary Tract Cancers

scholarly journals Chronic Viral Hepatitis Signifies the Association of Premixed Insulin Analogues with Liver Cancer Risks: A Nationwide Population-Based Study

2019 ◽  
Vol 16 (12) ◽  
pp. 2097 ◽  
Author(s):  
Chien-Hsieh Chiang ◽  
Chia-Sheng Kuo ◽  
Wan-Wan Lin ◽  
Jun-Han Su ◽  
Jin-De Chen ◽  
...  
Keyword(s):  
Viral Hepatitis ◽  
Population Based ◽  
Insulin Analogues ◽  
Chronic Viral Hepatitis ◽  
Premixed Insulin ◽  
Population Based Study ◽  
Before And After ◽  
Nested Case Control

This study sought to determine whether chronic hepatitis B or C would modify the association between insulin analogues and hepatocellular carcinoma (HCC) risks. We conducted a nationwide nested case-control study for HCC cases and matched controls from 2003 to 2013 among newly diagnosed type 2 diabetes patients on any antidiabetic agents in Taiwan before and after exclusion of chronic viral hepatitis, respectively. A total of 5832 and 1237 HCC cases were identified before and after exclusion of chronic viral hepatitis, respectively. Incident HCC risks were positively associated with any use of premixed insulin analogues (adjusted odds ratio (OR), 1.27; 95% CI 1.04 to 1.55) among total participants, especially among current users (adjusted OR, 1.45; 95% CI 1.12 to 1.89). However, the association between HCC occurrence and premixed insulin analogues diminished among participants without chronic viral hepatitis (adjusted OR, 1.35; 95% CI 0.92 to 1.98). We also observed a significant multiplicative interaction between chronic viral hepatitis and premixed insulin analogues on HCC risks (P = 0.010). Conclusions: Chronic viral hepatitis signifies the role of premixed insulin analogues in HCC oncogenesis. We recommend a closer liver surveillance among patients prescribed premixed insulin analogues with concomitant chronic viral hepatitis.

Sign in / Sign up

Export Citation Format

Share Document